Evaluating a new T cell-engaging antibody for B-cell cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a T cell-engaging antibody that targets CD20, in patients with relapsed or refractory B-cell malignancies. Participants will receive the experimental treatment to determine its tolerability and effectiveness after having undergone at least two prior lines of therapy. The study will include various types of B-cell neoplasms, such as large B-cell lymphoma and chronic lymphocytic leukemia, and will monitor participants for adverse effects and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years of age;
* Histologically documented CD20+ mature B-cell neoplasm

  * Large B-cell lymphoma
  * Follicular lymphoma
  * Mantle cell lymphoma
  * Chronic lymphocytic leukemia
  * Small lymphocytic lymphoma
* Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy;
* ECOG performance status of ≤ 2 (\< 2 in EU countries).

The above is a summary, other inclusion criteria details may apply.

Exclusion Criteria:

* Any neoplasm histology not specified in the IC section;
* Active CNS involvement in lymphoma;
* CNS pathology including but not limited to any history of seizure disorder/epilepsy;
* Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy;
* History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS;
* Active and uncontrolled infections;
* Unresolved AEs ≥2 Grade due to prior anticancer therapies, with some exceptions

The above is a summary, other exclusion criteria details may apply.

Where it's running

• Research Site
  La Jolla, California, United States Recruiting
• Research Site
  Rochester, Minnesota, United States Recruiting
• Research Site
  Hackensack, New Jersey, United States Recruiting
• Research Site
  New York, New York, United States Recruiting
• Research Site
  New York, New York, United States Recruiting
• Research Site
  Charlotte, North Carolina, United States Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CD19-targeted mRNA therapy delivered by lipid nanoparticles for B-cell blood cancers

  It will try a lipid-nanoparticle mRNA therapy that generates CD19-targeted CAR-T activity inside the body for adults (18–70) with relapsed or refractory CD19-positive B-cell leukemia or lymphoma who have no standard treatment options.

  Recruiting Early Phase 1 Xinqiao Hospital of Chongqing · Chongqing, Chongqing Municipality · NCT07349849

• Emavusertib plus zanubrutinib for CLL and other B‑cell cancers

  This test will see if adding emavusertib to the BTK inhibitor zanubrutinib can reduce measurable residual disease in adults with chronic lymphocytic leukemia or other B‑cell malignancies.

  Recruiting at 11 sites Phase 2 Curis, Inc. · Miami Beach, Florida and 10 other locations · NCT07271667

• Anti-CD22 CAR‑T cell therapy for CD22‑positive B‑cell cancers

  This trial will try a one-time CAR‑T cell therapy that targets CD22 in children and adults whose relapsed or refractory B‑cell cancers still express CD22 after prior treatments, including CD19‑directed therapy.

  Recruiting Phase 1/2 Sheba Medical Center · Ramat Gan, G · NCT07135466

• JY231 injection for relapsed or refractory CD19-positive B-cell malignancies

  This trial will test whether a single intravenous injection of JY231, an in vivo CAR-T therapy, can help adults with relapsed or refractory CD19-positive B-cell malignancies.

  Recruiting 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Kunming, Yunnan · NCT07065279

• Evaluating SYS6005 for advanced malignant tumors

  This study is testing a new treatment called SYS6005 to see if it is safe and effective for people with advanced malignant tumors.

  Recruiting Phase 1 CSPC Megalith Biopharmaceutical Co.,Ltd. · Tianjin · NCT06958679

• Treatment with anti-CD19-CAR-T cells for patients with relapsed B-cell tumors

  This study is testing a new treatment using anti-CD19-CAR-T cells to see if it can help patients with relapsed B-cell tumors feel better.

  Recruiting Early Phase 1 Shanghai Tongji Hospital, Tongji University School of Medicine · Shanghai, Shanghai Municipality · NCT06375161

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.